Targeting the body's response to low oxygen levels to treat a serious fungal infection.
Therapeutic targeting the host hypoxia-response pathway to treat Mucormycosis
This study is looking at how we can improve treatments for Mucormycosis, a serious fungal infection that affects people with weakened immune systems, by exploring new ways to help the body respond better to the infection, and patients may have the chance to try out these new treatment methods.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11127298 on NIH RePORTER |
What this research studies
This research focuses on Mucormycosis, a severe fungal infection that primarily affects individuals with weakened immune systems or underlying health conditions. The study aims to explore how manipulating the body's hypoxia-response pathway can enhance treatment effectiveness against this infection. By investigating new therapeutic approaches, the research seeks to improve patient outcomes where current antifungal treatments have limited success. Patients may be involved in trials that assess the safety and efficacy of these novel treatment strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with compromised immune systems, such as those undergoing chemotherapy, organ transplant recipients, or patients with uncontrolled diabetes.
Not a fit: Patients with healthy immune systems or those not at risk for Mucormycosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for Mucormycosis, potentially reducing mortality rates associated with this infection.
How similar studies have performed: While the approach of targeting the hypoxia-response pathway is innovative, similar strategies in other fungal infections have shown promise, indicating potential for success in this area.
Where this research is happening
Baltimore, United States
- University of Maryland Baltimore — Baltimore, United States (Active)
Researchers
- Principal investigator: Bruno, Vincent Michael — University of Maryland Baltimore
- Study coordinator: Bruno, Vincent Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.